X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-06-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $24.19 | -14,474 | 57,095 | -20% | -$350,087 | |||||
| D | 2026-06-17 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $25.00 | -3,000 | 6,200 | -33% | -$75,000 | |||||
2026-06-15 | ARQT | Arcutis Biotherapeutics, Inc. | Lin Sue-Jean | Dir | S - Sale | $24.38 | -4,946 | 27,567 | -15% | -$120,587 | ||||||
| DM | 2026-06-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $24.58 | -4,731 | 37,743 | -11% | -$116,281 | |||||
| D | 2026-06-15 | SDEV | Stablecoin Development Corp | Kazley Michael John | CEO, 10% | S - Sale+OE | $1.09 | -24,720 | 22,668,516 | 0% | -$26,945 | |||||
| D | 2026-06-15 | SDEV | Stablecoin Development Corp | Framework Ventures IV L.P. | 10% | S - Sale+OE | $1.09 | -24,720 | 22,668,516 | 0% | -$26,945 | |||||
| D | 2026-06-15 | SDEV | Stablecoin Development Corp | R01 Fund LP | 10% | S - Sale+OE | $1.09 | -24,720 | 22,668,516 | 0% | -$26,945 | |||||
2026-06-15 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $16.39 | -13,314 | 232,457 | -5% | -$218,167 | ||||||
2026-06-15 | ELVN | Enliven Therapeutics, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $45.02 | -281,408 | 7,388,902 | -4% | -$12,668,988 | ||||||
| M | 2026-06-17 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.04 | +335,759 | 117,042,473 | 0% | +$15,013 | |||||
2026-06-15 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $60.71 | -5,538 | 15,437 | -26% | -$336,212 | ||||||
2026-06-15 | CTMX | Cytomx Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale | $3.05 | -1,624 | 295,324 | -1% | -$4,953 | ||||||
| M | 2026-06-15 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $19.01 | -150,000 | 2,859,940 | -5% | -$2,851,000 | |||||
2026-06-15 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $31.07 | -2,291 | 1,085,209 | 0% | -$71,173 | ||||||
| D | 2026-06-15 | IMNM | Immunome Inc. | Rosett Max | CFO | S - Sale+OE | $18.23 | -60,000 | 54,037 | -53% | -$1,093,800 | |||||
| D | 2026-06-17 | ETON | Eton Pharmaceuticals, Inc. | Adams Jennifer McKie | Dir | S - Sale+OE | $32.48 | -50,000 | 0 | -100% | -$1,623,795 | |||||
| D | 2026-06-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $549.80 | -9,500 | 668,728 | -1% | -$5,223,068 | |||||
| D | 2026-06-15 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale+OE | $27.85 | -10,000 | 43,254 | -19% | -$278,500 | |||||
2026-06-15 | QURE | Uniqure N.V. | Potts Jeannette | GC | S - Sale | $27.67 | -5,237 | 133,246 | -4% | -$144,908 | ||||||
2026-06-15 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $10.19 | +1,000 | 17,592 | +6% | +$10,190 | ||||||
2026-06-15 | JAZZ | Jazz Pharmaceuticals Plc | Smith Mark Douglas | Dir | S - Sale | $230.55 | -1,157 | 9,680 | -11% | -$266,746 | ||||||
| D | 2026-06-15 | BBIO | Bridgebio Pharma, Inc. | Cook Jennifer E. | Dir | S - Sale+OE | $66.62 | -90,240 | 6,589 | -93% | -$6,012,157 | |||||
2026-06-15 | CMND | Clearmind Medicine Inc. | Hrt Financial LP | 10% | S - Sale | $3.32 | -3,183 | 103,492 | -3% | -$10,568 | ||||||
2026-06-16 | IRWD | Ironwood Pharmaceuticals Inc | McHugh Julie | Dir | S - Sale | $3.73 | -21,571 | 250,749 | -8% | -$80,460 | ||||||
| D | 2026-06-15 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $81.15 | -40,000 | 16,130 | -71% | -$3,245,900 | |||||
2026-06-16 | NRSN | Neurosense Therapeutics Ltd. | Eisenberg Or | CFO | P - Purchase | $0.80 | +250,000 | 1,504,050 | +20% | +$200,000 | ||||||
2026-06-16 | NRSN | Neurosense Therapeutics Ltd. | Ben-Noon Alon | CEO | P - Purchase | $0.80 | +250,000 | 4,534,233 | +6% | +$200,000 | ||||||
2026-06-15 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.01 | +2,114,344 | 344,964 | -119% | +$29,601 | ||||||
2026-06-16 | KRRO | Korro Bio, Inc. | Chappell Todd | COO | S - Sale | $10.83 | -3,168 | 16,964 | -16% | -$34,309 | ||||||
2026-06-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -4,062 | 16,953 | -19% | -$1,827,900 | ||||||
2026-06-16 | KRRO | Korro Bio, Inc. | Vincent Loic A | Chief Scientific Officer | S - Sale | $10.83 | -3,418 | 18,297 | -16% | -$37,017 | ||||||
2026-06-16 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $18.33 | -887 | 169,155 | -1% | -$16,259 | ||||||
2026-06-16 | KRRO | Korro Bio, Inc. | Cerio Jeffrey | GC | S - Sale | $10.83 | -6,609 | 35,293 | -16% | -$71,575 | ||||||
2026-06-16 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $18.33 | -145 | 154,208 | 0% | -$2,658 | ||||||
2026-06-16 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $18.33 | -2,683 | 440,151 | -1% | -$49,179 | ||||||
2026-06-16 | KRRO | Korro Bio, Inc. | Dolan Oliver | SVP, Finance | S - Sale | $10.83 | -3,383 | 18,099 | -16% | -$36,638 | ||||||
2026-06-15 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $8.60 | +705 | 137,268 | +1% | +$6,059 | ||||||
2026-06-16 | UPB | Upstream Bio, Inc. | Gray Michael | CFO, COO | S - Sale | $6.10 | -853 | 28,795 | -3% | -$5,203 | ||||||
2026-06-16 | UPB | Upstream Bio, Inc. | Sutherland Everett Rand | CEO | S - Sale | $6.10 | -2,095 | 70,812 | -3% | -$12,780 | ||||||
2026-06-16 | UPB | Upstream Bio, Inc. | Houghton Adam | Chief Business Officer | S - Sale | $6.10 | -700 | 23,601 | -3% | -$4,270 | ||||||
2026-06-16 | UPB | Upstream Bio, Inc. | Deykin Aaron | Chief Medical Officer | S - Sale | $6.10 | -895 | 33,197 | -3% | -$5,460 | ||||||
2026-06-16 | UPB | Upstream Bio, Inc. | Ambrose Allison | GC | S - Sale | $6.10 | -477 | 16,048 | -3% | -$2,910 | ||||||
2026-06-15 | XNCR | Xencor Inc | Gorman Kevin Charles | Dir | S - Sale | $12.31 | -7,527 | 11,378 | -40% | -$92,657 | ||||||
| D | 2026-06-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $5.67 | -41,666 | 1,724,564 | -2% | -$236,346 | |||||
2026-06-15 | XNCR | Xencor Inc | Gustafson Kurt A | Dir | S - Sale | $12.31 | -5,474 | 14,709 | -27% | -$67,385 | ||||||
2026-06-15 | XNCR | Xencor Inc | Ranieri Richard J | Dir | S - Sale | $12.31 | -5,474 | 13,709 | -29% | -$67,385 | ||||||
2026-06-15 | XNCR | Xencor Inc | Montgomery Alan Bruce | Dir | S - Sale | $12.31 | -5,064 | 15,547 | -25% | -$62,338 | ||||||
2026-06-16 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.64 | +2,836 | 972,170 | 0% | +$7,487 | ||||||
2026-06-16 | BLTE | Belite Bio, Inc | Scholl Hendrik Peter | Chief Medical Officer | S - Sale | $140.57 | -10,000 | 25,000 | -29% | -$1,405,729 | ||||||
| D | 2026-06-12 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $35.08 | -6,250 | 793 | -89% | -$219,224 | |||||
| M | 2026-06-12 | PBLS | Parabilis Medicines, Inc. | Sebulsky Alan | Dir | P - Purchase | $27.06 | +17,500 | 30,000 | +140% | +$473,529 | |||||
| M | 2026-06-12 | HOWL | Werewolf Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.39 | -448,836 | 331,414 | -58% | -$173,758 | |||||
| D | 2026-06-12 | IONS | Ionis Pharmaceuticals Inc | Kordasiewicz Holly B. | EVP, Chief Development Officer | S - Sale+OE | $73.41 | -60,846 | 22,458 | -73% | -$4,466,428 | |||||
| D | 2026-06-15 | IONS | Ionis Pharmaceuticals Inc | Berthelsen Spencer R | Dir | S - Sale+OE | $73.49 | -8,000 | 156,083 | -5% | -$587,920 | |||||
| D | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale+OE | $50.07 | -10,000 | 56,250 | -15% | -$500,747 | |||||
| D | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $50.00 | -4,500 | 41,500 | -10% | -$225,000 | |||||
| D | 2026-06-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $549.15 | -9,500 | 668,728 | -1% | -$5,216,918 | |||||
| D | 2026-06-15 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $549.17 | -10,000 | 18,876 | -35% | -$5,491,742 | |||||
| M | 2026-06-12 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $71.45 | -196,111 | 1,045,785 | -16% | -$14,012,580 | |||||
2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.22 | +2,067 | 21,881 | +10% | +$4,589 | ||||||
2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.22 | +2,654 | 13,412 | +25% | +$5,892 | ||||||
2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.22 | +2,465 | 16,723 | +17% | +$5,472 | ||||||
2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.22 | +1,831 | 12,747 | +17% | +$4,065 | ||||||
2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.22 | +2,118 | 12,291 | +21% | +$4,702 | ||||||
2026-06-16 | DRMA | Dermata Therapeutics, Inc. | Scott Kathleen D. | Dir | S - Sale | $1.19 | -11 | 1 | -92% | -$13 | ||||||
2026-06-15 | IMRX | Immuneering Corp | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | P - Purchase | $4.15 | +6,035 | 382,531 | +2% | +$25,045 | ||||||
2026-06-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.16 | -25,000 | 635,574 | -4% | -$104,010 | ||||||
2026-06-12 | CMND | Clearmind Medicine Inc. | Hrt Financial LP | 10% | S - Sale | $3.36 | -2,102 | 106,675 | -2% | -$7,063 | ||||||
2026-06-12 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.02 | +4,252,767 | 2,459,308 | -237% | +$68,044 | ||||||
2026-06-12 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.50 | +21,000 | 630,812 | +3% | +$52,500 | ||||||
2026-06-11 | TEVA | Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, CFO | S - Sale | $34.10 | -106,563 | 65,621 | -62% | -$3,633,308 | ||||||
| D | 2026-06-12 | LGND | Ligand Pharmaceuticals Inc | Haas Jason | Dir | S - Sale+OE | $255.58 | -6,461 | 4,981 | -56% | -$1,651,320 | |||||
| M | 2026-06-11 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | COB, CEO, Interim CFO, 10% | S - Sale | $3.88 | -18,124 | 332,715 | -5% | -$70,352 | |||||
2026-06-12 | PBYI | Puma Biotechnology, Inc. | Wilson Troy Edward | Dir | S - Sale | $7.20 | -10,800 | 60,300 | -15% | -$77,748 | ||||||
2026-06-12 | PBYI | Puma Biotechnology, Inc. | Stuglik Brian M | Dir | S - Sale | $7.20 | -8,100 | 113,858 | -7% | -$58,311 | ||||||
2026-06-12 | PBYI | Puma Biotechnology, Inc. | Senderowicz Adrian | Dir | S - Sale | $7.20 | -27,000 | 27,000 | -50% | -$194,311 | ||||||
2026-06-12 | PBYI | Puma Biotechnology, Inc. | Moyes Jay M | Dir | S - Sale | $7.22 | -22,000 | 58,322 | -27% | -$158,796 | ||||||
2026-06-12 | PBYI | Puma Biotechnology, Inc. | Dorval Allison | Dir | S - Sale | $7.20 | -11,610 | 90,780 | -11% | -$83,579 | ||||||
2026-06-15 | ABEO | Abeona Therapeutics Inc. | Silverstein Christine Berni | Dir | S - Sale | $5.71 | -18,160 | 119,562 | -13% | -$103,695 | ||||||
| D | 2026-06-11 | PBLS | Parabilis Medicines, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $20.00 | +21,188,750 | 2,648,278 | -114% | +$423,775,000 | |||||
| DM | 2026-06-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $69.72 | -9,854 | 16,899 | -37% | -$687,035 | |||||
| D | 2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $69.28 | -7,947 | 32,718 | -20% | -$550,607 | |||||
2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale | $69.69 | -1,729 | 925,580 | 0% | -$120,494 | ||||||
2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale | $69.69 | -600 | 236,384 | 0% | -$41,814 | ||||||
2026-06-15 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Dir | S - Sale | $25.05 | -2,000 | 21,095 | -9% | -$50,100 | ||||||
2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale | $69.69 | -733 | 31,034 | -2% | -$51,083 | ||||||
2026-06-15 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $24.62 | -1,899 | 94,462 | -2% | -$46,753 | ||||||
2026-06-12 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $82.03 | -500 | 77,890 | -1% | -$41,015 | ||||||
2026-05-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $18.91 | -388 | 73,878 | -1% | -$7,337 | ||||||
2026-05-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $18.92 | -130 | 17,808 | -1% | -$2,460 | ||||||
2026-05-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $18.92 | -89 | 17,894 | 0% | -$1,684 | ||||||
2026-05-11 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $18.91 | -217 | 15,420 | -1% | -$4,103 | ||||||
2026-06-12 | NATR | Natures Sunshine Products Inc | Herbert Kevin R. | EVP, Pres, North America | S - Sale | $20.68 | -2,000 | 48,866 | -4% | -$41,364 | ||||||
2026-06-11 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale | $257.20 | -169 | 99,645 | 0% | -$43,467 | ||||||
| D | 2026-06-11 | ONC | Beone Medicines Ltd. | Wang Lai | Pres, Global Head of R, D | S - Sale+OE | $261.00 | -756 | 2,312,050 | 0% | -$197,318 | |||||
| D | 2026-06-11 | ONC | Beone Medicines Ltd. | Rosenberg Aaron | CFO | S - Sale+OE | $257.74 | -631 | 397,891 | 0% | -$162,637 | |||||
| D | 2026-06-11 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale+OE | $261.20 | -626 | 1,324,526 | 0% | -$163,512 | |||||
| D | 2026-06-11 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $257.64 | -428 | 346,554 | 0% | -$110,268 | |||||
| D | 2026-06-11 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $257.24 | -1,949 | 51,729,643 | 0% | -$501,355 | |||||
| D | 2026-06-11 | CRVO | Cervomed Inc. | Boger Joshua S | Dir, 10% | P - Purchase | $3.14 | +955,414 | 2,012,682 | +90% | +$3,000,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |